Large blind test shows AI-designed antibodies bind well but face generalization challenges

A Nature Biotechnology study reports the first large blind test of AI-designed antibodies, with 29 labs evaluating 511 binders designed without target structure knowledge. Some matched drug-level binding potency, though most AI-native methods still struggle with generalization and developability.

2026-08-21 ~ 2026-08-22 · 2 related posts